L-97-1

About Endacea

Endacea is a long-standing, privately-held biotech firm leveraging deep expertise in A1 adenosine receptor biology to develop novel therapeutics. Its pipeline features two lead preclinical assets: L-97-1, a 'best-in-class' A1 antagonist for sepsis and acute renal failure, and a mutant plasmid cDNA A1 receptor gene therapy for cancer. The company is led by its founder, Dr. Constance Neely Wilson, and seeks partnerships and investment to advance its virtual R&D efforts towards clinical trials.

Therapeutic Areas